Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-6-415 in Advanced or Metastatic Solid Tumors with RAS or RAF Mutations
NCT06208124Phase 2Completed
- Sponsor
- Immuneering Corporation
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMM-6-415 in solid tumor (advanced stage), pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), Malignant Melanoma (MM), sponsored by Immuneering Corporation. Started Feb 2024; status: completed.
02
Drugs
IMM-6-415
03
Conditions
solid tumor (advanced stage)pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06208124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208124.